Venture capital firm's Chinese investment to be reviewed by U.S. Treasury; Small-scale M&A on the rise despite trade tensions, sluggish growth; and U.S. Congressmen urge delisting of 25 Chinese groups from U.S. exchanges.
CATL and Ant Group’s planned listings could break recent HK IPO records; The lowering of U.S. drug prices will impact Chinese drugmakers; and U.S. House passes sanctions bill targeting trade secret theft by China.
China eases cross-border data transfer restrictions for financial institutions; Trade war prompts plan to open up service sector; and new law firm anti-money laundering regulations to align with international standards
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
Hong Kong stock market rebounds when Chinese government halts Swiss listings; China backs AI with government investment fund; and China’s Supreme People’s Court further protects intellectual property rights in apple plant varieties.
China clamps down on small-cap U.S. listings by Chinese issuers; China mandates personal information protection compliance audits for companies; and AI company loses against Reuters in U.S. summary judgment with key implication
Trump signs memorandum to restrict investments that do not serve American interests; A Jiangsu court ruled that investments in overseas crypto projects are not protected under Chinese law; and Chinese companies raise funds in hope of easing of regulations against private enterprises
U.S. attempts to exclude Chinese access to AI chips by designating ‘gatekeeper’ companies; Shein’s UK IPO application scrutinized over forced labor concerns; and China’s AI Standards Committee to include executives from tech giants
